Scarica l'app Stockscreener
22.00
0.50%
-0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
Celldex stock price target maintained at $50 by H.C. Wainwright - Investing.com Canada
Global Personalized Cancer Vaccine Market | Immunotherapy - openPR.com
Q2 Earnings Estimate for CLDX Issued By Lifesci Capital - Defense World
Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded - Asianet Newsable
Celldex Therapeutics (NASDAQ:CLDX) Earns “Buy” Rating from HC Wainwright - Defense World
Celldex Presents Data Demonstrating Profound Long Term Improvement In Angioedema In Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci 2025 - MarketScreener
Celldex Presents Data Demonstrating Profound Long Term - GlobeNewswire
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire Inc.
Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Targ - GuruFocus
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges By Investing.com - Investing.com South Africa
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges - Investing.com
Celldex Therapeutics Inc (CLDX) Stock: A Comprehensive 52-Week Review - investchronicle.com
Celldex shares jump on impressive skin disorder drug data By Investing.com - Investing.com Canada
Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Target | CLDX Stock News - GuruFocus
Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data - Endpoints News
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - Benzinga
Celldex stock maintains Overweight rating on promising CSU therapy results By Investing.com - Investing.com Canada
Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics - Benzinga
Celldex Presents Unprecedented 76 Week Results from - GlobeNewswire
Transcript : Celldex Therapeutics, Inc.Special Call - marketscreener.com
Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com
Celldex (CLDX) Unveils Promising Data for Barzolvolimab in Treating Chronic Urticaria | CLDX Stock News - GuruFocus
Breakthrough: Celldex CSU Drug Maintains Complete Response 7 Months After Treatment Ends - Stock Titan
Celldex stock rating reiterated at Buy by Canaccord ahead of data release - Investing.com Nigeria
One Celldex Therapeutics Insider Raised Stake By 40% In Previous Year - simplywall.st
Eric Sprott buying at Silver Storm Mining (SVRS) - The Globe and Mail
Analysts Set Expectations for CLDX FY2026 Earnings - Defense World
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress - GlobeNewswire
Groundbreaking 76-Week Chronic Urticaria Treatment Data: Celldex's Barzolvolimab Results Coming to EAACI - Stock Titan
Celldex Therapeutics appoints new board member By Investing.com - Investing.com South Africa
Celldex Therapeutics Appoints Denice Torres To Board - citybiz
Celldex Therapeutics appoints new board member - Investing.com
Celldex Approves Equity Plan Amendment and Elects New Director - TipRanks
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors - Yahoo Finance
Prurigo Nodularis Pipeline 2025: FDA Updates, Therapy - openPR.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth By Investing.com - Investing.com South Africa
Global Cholera Vaccines Market in 2025-2032 Detailed Study - openPR.com
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth - Investing.com India
BNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Morgan Stanley Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $43.00 - Defense World
UBS Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $38.00 - Defense World
The Goldman Sachs Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $31.00 - Defense World
Hsbc Holdings PLC Takes $233,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics Q1 2025 Earnings: EPS of ($0.81) Misses Est - GuruFocus
UBS Lowers Price Target for Celldex Therapeutics (CLDX) to $38 | - GuruFocus
First Trust Advisors LP Trims Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
H.C. Wainwright cuts Celldex stock price target to $50 from $80 - Investing.com Nigeria
Celldex Therapeutics (CLDX): Analyst Lowers Price Target But Mai - GuruFocus
Morgan Stanley Updates Price Target for Celldex Therapeutics (CL - GuruFocus
Goldman Sachs Lowers Price Target for Celldex Therapeutics (CLDX) | CLDX Stock News - GuruFocus
Celldex (CLDX) Target Price Reduced by Analyst Following Q1 Repo - GuruFocus
UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating - marketscreener.com
Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):